|Other Names||Pachytene checkpoint protein 2 homolog, Human papillomavirus type 16 E1 protein-binding protein, 16E1-BP, HPV16 E1 protein-binding protein, Thyroid hormone receptor interactor 13, Thyroid receptor-interacting protein 13, TR-interacting protein 13, TRIP-13, TRIP13, PCH2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2843a was selected from the N-term region of human TRIP13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Plays a key role in chromosome recombination and chromosome structure development during meiosis. Required at early steps in meiotic recombination that leads to non-crossovers pathways. Also needed for efficient completion of homologous synapsis by influencing crossover distribution along the chromosomes affecting both crossovers and non-crossovers pathways. Also required for development of higher-order chromosome structures and is needed for synaptonemal-complex formation. In males, required for efficient synapsis of the sex chromosomes and for sex body formation. Promotes early steps of the DNA double- strand breaks (DSBs) repair process upstream of the assembly of RAD51 complexes. Required for depletion of HORMAD1 and HORMAD2 from synapsed chromosomes (By similarity).|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
TRIP13 specifically interacts with the ligand binding domain of the thyroid receptor (TR). This interaction does not require the presence of thyroid hormone for its interaction.
Rush,J., Nat. Biotechnol. 23 (1), 94-101 (2005)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.